Loading data for PEPG — first visit, this takes a few seconds.
PepGen Inc.
3.11 -0.07 (-2.20%)
3.04 +2.18%
- Market Cap
- $206.1M
- Volume
- 201K
- Dividend yield
- n/a
- Next earnings date
- Nov 11, 2026
PepGen Inc. (PEPG) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $0 | n/a | n/a |
| EPS | -$0.26 | +$0.02 | +71.74% |
Metrics
- Bid
- 2.29
- Market Cap
- 206M
- Revenue (ttm)
- n/a
- Net Income (ttm)
- -71.9M
- 1.97
- -1
- n/a
- -2.87
- P/B (ttm)
- 1.72
- P/S (ttm)
- n/a
- Earnings Date
- Nov 11, 2026
- Ask
- 3.98
- Volume
- 201,000
- Avg. Volume (20D)
- 924,519
- Open
- 3.14
- Previous Close
- 3.18
- Day's Range
- 3.10 - 3.19
- 52-Week Range
- 1.31 - 7.80
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About PepGen Inc.
View profile →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Industry Biotechnology
Sector Healthcare
IPO Date May 6, 2022
Employees 57
Stock Exchange NasdaqGS
Ticker Symbol PEPG
Website https://www.pepgen.com